Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 3/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20731189 | 0.81 | CLK4 (0.44) | VNN1PDE5AHDAC3HDAC1HDAC2 | |
| SCHEMBL3795994 | 0.79 | HDAC3 (0.76) | VNN1PDE5AHDAC3HDAC1HDAC2 | |
| SCHEMBL23938073 | 0.79 | HDAC3 (0.45) | VNN1PDE5AHDAC3HDAC1HDAC2 | |
| SCHEMBL23938074 | 0.73 | CXCR4 (0.61) | PDE5ATSHRALDH1A1NPC1RAB9A | |
| SCHEMBL30465779 | 0.73 | VNN1 (0.70) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29410881 | 0.71 | TSHR (1.00) | TSHRNPC1RAB9ASMN1; SMN2CHEK2 | |
| SCHEMBL624490 | 0.71 | TSHR (1.00) | TSHRNPC1RAB9ASMN1; SMN2CHEK2 | |
| SCHEMBL31141723 | 0.71 | HDAC3 (0.82) | VNN1PDE5AHDAC3HDAC1HDAC2 | |
| SCHEMBL21704230 | 0.71 | AURKA (0.47) | HDAC3HDAC1HDAC2HDAC6NPC1 | |
| SCHEMBL22079499 | 0.69 | NNMT (0.45) | VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | VNN1 1865/4885PDE5A 3143/4885TSHR 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.